Drugs of Tomorrow 2002: Reperfusion Injury - The Next Breakthrough in Clinical Cardiology

SUMMARY

• Scope
• Datamonitor insight into the reperfusion injury market
• Key metrics

• Definition of reperfusion injury
• Ischemic injury
• Reperfusion injury
• Causes of reperfusion injury
• Myocardial stunning
• Indications for future reperfusion injury drugs
• Large patient population but considerable overlap
• Coronary artery bypass grafting
• Acute coronary syndromes
• Percutaneous transluminal coronary angioplasty (PTCA)
• Potential benefits of reperfusion injury
• Unmet need 1: Reduction in mortality
• Unmet need 2: Reduction in MI and other non-fatal adverse events
• Unmet need 3: Neurocognitive dysfunction
• Unmet need 4: Cost-effectiveness

• Classification of pipeline products
• Pharmacological approaches
• Ion channel modulators
• Artificial blood products
• Novel procedures and adjunctive devices
• Clinical trials in reperfusion injury – the perils and pitfalls
• Clinical trial endpoints in reperfusion injury

• Pipeline overview
• Pipeline analysis by development strategy
• Breakdown of compounds by stage of development
• Development breakdown by type of company
• Company involvement in reperfusion injury

• Overview of developmental drug therapies
• Immune modulators
• Pexelizumab
• Onercept (r-hTBP-1)
• Ion channel modulators
• Cariporide
• Adenosine
• Discontinued drugs
• Eniporide
• LeukArrest
• TP-10
• Blood replacement products
• Oxygent
• Hemopure
• Hemolink
• PolyHeme
• Procedures and devices
• Off-pump CABG (OPCAB)
• Anastomosis devices
• Robotic surgery

• Key phase I and pre-clinical compounds for reperfusion injury
• Immune modulators
• Vapantix (Vascular adhesion protein-1; VAP-1)
• RC522
• Anti-L Selectin Antibody
• VAS971
• ONO-5046
• CAB-2
• Ion channel modulators
• JTV-519
• AMP-579
• MC-1
• KB-R7943
• SM-20550
• EMD-87580
• CGS-21680C
• K-ATP channel activators
• Phosphorylase inhibitors
• CP-380867
• Blood oxygen enhancing products
• TherOx AO System
• HRC-102
• S-9156

• Introduction
• Comparative analysis of the most promising anti-reperfusion injury drugs
• Comparative analysis of the most promising blood replacement products
• Overview of likely market entry
• Efficacy
• Patient potential
• Cost
• Marketing strength

• Methodology
• Forecasting methodology in reperfusion injury
• Comparator
• Estimating the patient potential for reperfusion injury pipeline products
• Forecasting first year sales for pipeline drugs
• Summary of methodology
• Forecast launches in reperfusion injury drug from 2001 to 2008
• Market drivers in reperfusion injury
• Prospective drug launches in reperfusion injury
• Key R&D product forecasts

• Datamonitor's Cardiovascular Business Unit
• Bibliography
• Key conferences and associations
• Epidemiology methodology
• Sources for epidemeology
• Forecast methodology for CABG procedures
• Forecast methodology for AMI patients
• Forecast methodology for prevalence of PCI
• References
• R&D research methodology
• Introduction
• Hypothesis formulation
• Hypothesis testing
• Data verification and quality control